FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

by | June 10, 2025 2:04 am | US Markets

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.